HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LB42708

farnesyltransferase inhibitor; structure in first source

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - LB42708: 4
    - Imidazoles: 150
      - LB42708: 4

Experts

1.	Ha, Kwon-Soo: 2 articles (07/2010 - 07/2004)
2.	Kim, Young-Myeong: 2 articles (07/2010 - 07/2004)
3.	Kwon, Young-Guen: 2 articles (07/2010 - 07/2004)
4.	Lee, Hansoo: 2 articles (07/2010 - 07/2004)
5.	Cho, Yoon Chul: 1 article (10/2014)
6.	Jang, Byeong-Churl: 1 article (10/2014)
7.	Jang, Ji Hoon: 1 article (10/2014)
8.	Kim, Dong Eun: 1 article (10/2014)
9.	Kim, Ki Ho: 1 article (10/2014)
10.	Kim, Shin: 1 article (10/2014)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2010 - "LB42708 suppressed tumor growth and tumor angiogenesis in both xenograft tumor models of Ras-mutated HCT116 cells and its wild-type Caco-2 cells, indicating its potential application in the treatment of both Ras-mutated and wild type tumors. " 10/01/2014 - "Taken together, our results show that the activity of BAI plus LB42708 modulate multiple components in apoptotic response of human renal Caki cells, and indicate a potential as combinational therapeutic agents for preventing cancer such as renal carcinoma. " 07/01/2010 - "These data indicate that the antitumor effect of LB42708 can be associated with direct inhibition of VEGF-induced tumor angiogenesis by blocking Ras-dependent MAPK and PI3K/Akt signal pathways in tumor-associated endothelial cells." 01/01/2013 - "Other important FTIs such as BMS-214662, LB42908, LB42708, etc are under clinical studies for the treatment of various cancers. "
2.	Inflammation (Inflammations) 07/15/2004 - "We synthesized a potent and selective farnesyltransferase inhibitor (LB42708) with IC(50) values of 0.8 nM in vitro and 8 nM in cultured cells against p21(ras) farnesylation and examined the effects of this inhibitor in the settings of inflammation and arthritis. "
3.	Renal Cell Carcinoma (Grawitz Tumor) 10/01/2014 - "Taken together, our results show that the activity of BAI plus LB42708 modulate multiple components in apoptotic response of human renal Caki cells, and indicate a potential as combinational therapeutic agents for preventing cancer such as renal carcinoma. "
4.	Arthritis (Polyarthritis) 07/15/2004 - "Together, these findings reveal that the inhibitory effect of LB42708 on p21(ras)-dependent NF-kappaB activation may have potential therapeutic value for arthritis and other inflammatory diseases." 07/15/2004 - "We synthesized a potent and selective farnesyltransferase inhibitor (LB42708) with IC(50) values of 0.8 nM in vitro and 8 nM in cultured cells against p21(ras) farnesylation and examined the effects of this inhibitor in the settings of inflammation and arthritis. " 07/15/2004 - "Furthermore, in vivo administration of LB42708 significantly decreased the incidence and severity of arthritis as well as mRNA expression of inducible NO synthase, cyclooxygenase-2, TNF-alpha, and IL-1beta in the paws of collagen-induced arthritic mice compared with controls. "

Related Drugs and Biologics

1.	LB42908
2.	7- cyano- 2,3,4,5- tetrahydro- 1- (1H- imidazol- 4- ylmethyl)- 3- (phenylmethyl)- 4- (2- thienylsulfonyl)- 1H- 1,4- benzodiazepine (BMS 214662)
3.	Cyclooxygenase 2 (Cyclooxygenase-2)
4.	Farnesyltranstransferase (Farnesyltransferase)
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6.	Nitric Oxide Synthase (NO Synthase)
7.	NF-kappa B (NF-kB)
8.	Proto-Oncogene Proteins p21(ras)
9.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
10.	Messenger RNA (mRNA)